Eli Lilly and Company (NYSE:LLY) Shares Acquired by Chapman Investment Management LLC

Chapman Investment Management LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,028 shares of the company’s stock after acquiring an additional 218 shares during the quarter. Eli Lilly and Company makes up 1.7% of Chapman Investment Management LLC’s portfolio, making the stock its 18th biggest position. Chapman Investment Management LLC’s holdings in Eli Lilly and Company were worth $2,338,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Timber Creek Capital Management LLC lifted its stake in shares of Eli Lilly and Company by 0.7% in the fourth quarter. Timber Creek Capital Management LLC now owns 12,717 shares of the company’s stock worth $9,818,000 after acquiring an additional 85 shares in the last quarter. Allied Investment Advisors LLC lifted its stake in shares of Eli Lilly and Company by 7.1% in the fourth quarter. Allied Investment Advisors LLC now owns 270 shares of the company’s stock worth $208,000 after acquiring an additional 18 shares in the last quarter. Atlas Legacy Advisors LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $590,000. Bank of Jackson Hole Trust bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $1,867,000. Finally, Klingman & Associates LLC increased its holdings in Eli Lilly and Company by 4.0% in the fourth quarter. Klingman & Associates LLC now owns 1,725 shares of the company’s stock valued at $1,332,000 after buying an additional 66 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LLY shares. Truist Financial boosted their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Wells Fargo & Company lowered their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Finally, Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $866.69 on Thursday. The firm has a market capitalization of $822.77 billion, a price-to-earnings ratio of 74.01, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The business has a 50 day simple moving average of $797.80 and a 200 day simple moving average of $845.87.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.69%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is 51.24%.

Eli Lilly and Company announced that its board has authorized a share repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.